Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A

摘要: Summary. Background: Most patients with severe hemophilia A suffer from a profoundly compromised hemostatic response. In addition to both the delayed and slow development of clot, previous studies have documented that is also associated reduced clot stability.Objectives: We examined whether stability in hemophiliacs could be improved by treatment tranexamic acid (TXA) combination recombinant factor VIII (rFVIII).Patients/methods: Baseline blood samples were obtained eight males A. Thereafter, bolus injection rFVIII was administered increase functional level FVIII ∼50%. After 10 min, collected followed an intravenous TXA. third sample after further 10 min. Whole clotting profiles determined thrombelastography using minimal tissue activation. Clot formation assessed initiation propagation. At termination, maximum firmness area under elasticity curve used illustrate stability. Tissue-plasminogen activator included those experiments designed assess Results: As expected, increased formation, whereas TXA had no effect upon this parameter. Assays including tissue-plasminogen revealed 3-fold; presence induced additional 4-fold increase. The 5-fold 24-fold Conclusions: The study demonstrates simultaneous significantly improves